Cholesterol efflux capacity in vitro predicts the severity and extent of coronary artery disease in patients with and without type 2 diabetes

Scandinavian Cardiovascular Journal

Volumn 35, Issue 2, 2001, Pages 96-100

  Pajunen, Pia ^a   Syvänne, Mikko ^a   Castro, Graciela ^b   Nieminen, Markku S ^a   Taskinen, Marja Riitta ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Cholesterol efflux; Coronary angiography; Coronary disease; Diabetes mellitus; Type 2

Indexed keywords

CHOLESTEROL;

ADULT; ANGIOCARDIOGRAPHY; ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROMA; CELL CULTURE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; HEPATOMA CELL; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT;

AGED; ANIMALS; CHOLESTEROL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RATS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 17144455370     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/140174301750164736     Document Type: Article

References (24)

1. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36: 211-228.
2. Von Eckardstein A, Assman G. High density lipoproteins and reverse cholesterol transport: Lessons from mutations. Atherosclerosis 1998; 137 Suppl: S7-S11.
3. Taskinen MR. Hyperlipidaemia in diabetes. Baillieres Clin Endocrinol Metab 1990; 4: 743-775.
4. Syvänne M, Castro G, Dengremont C, et al. Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes. Importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis 1996; 127: 245-253.
5. Syvänne M, Kahri J, Virtanen KS, Taskinen MR. HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. Circulation 1995; 92: 364-370.
6. Pajunen P, Nieminen MS, Taskinen MR, Syvänne M. Quantitative comparison of angiographic characteristics of coronary artery disease in patients with noninsulin-dependent diabetes mellitus compared with matched nondiabetic control subjects. Am J Cardiol 1997; 80: 550-556.
7. Syvänne M, Pajunen P, Kahri J, et al. Determinants of the angiographic severity and extent of coronary artery disease in patients with type 2 diabetes and in nondiabetic subjects. Coron Artery Dis 2001; (in press).
8. Reiber JCH, van der Zwet PMJ, von Land CD, et al. Quantitative coronary arteriography: Equipment and technical requirements. In: Reiber JCH, Serruys PW, editors. Advances in quantitative coronary arteriography. Dordrecht: Kluwer Academic, 1993: 75-111.
9. De la Llera Moya M, Atger V, Paul JL, et al. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb 1994; 14: 1056-1065.
10. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999; 22: 336-345.
11. Marcil M, Brooks-Wilson A, Clee SM, et al. Mutations in the ABC1 gene in familiar HDL deficiency with defective cholesterol efflux. Lancet 1999; 354: 1341-1346.
12. Fidge NH. High density lipoprotein receptors, binding proteins, and ligands. J Lipid Res 1999; 40: 187-201.
13. Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998; 19 Suppl A: A31-A35.
14. Rothblat GH, de la Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL, Phillips MC. Cell cholesterol efflux: Integration of old and new observations provides new insights. J Lipid Res 1999; 40: 781-796.
15. Fournier N, Paul JL, Atger V, et al. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol 1997; 17: 2685-2691.
16. Gillotte KL, Lund-Katz S, de la Llera-Moya M, et al. Dietary modification of high density lipoprotein phospholipid and influence on cellular cholesterol efflux. J Lipid Res 1998; 39: 2065-2075.
17. Igau B, Castro G, Clavey V, et al. In vivo glucosylated LpA-I subfraction. Evidence for structural and functional alterations. Arterioscler Thromb Vasc Biol 1997; 17: 2830-2836.
18. Rashduni DL, Rifici VA, Schneider SH, Khachadurian AK. Glycation of high-density lipoprotein does not increase its susceptibility to oxidation or diminish its cholesterol efflux capacity. Metabolism 1999; 48: 139-143.
19. Castro G, Nihoul LP, Dengremont C, et al. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Biochemistry 1997; 36: 2243-2249.
20. Han H, Sasaki J, Matsunaga A, et al. A novel mutant, apoA-I Nichinan (Glu235→ 0), is associated with low HDL cholesterol levels and decreased cholesterol efflux from cells. Arterioscler Thromb Vasc Biol 1999; 19: 1447-1455.
21. Decossin C, Castro G, Derudas B, Bertrand M, Fruchart JC, Fievet C. Subclasses of LpA-I in coronary artery disease: Distribution and cholesterol efflux ability. Eur J Clin Invest 1997; 27: 299-307.
22. Miida T, Nakamura Y, Inano K, et al. Pre beta 1-high-density lipoprotein increases in coronary artery disease. Clin Chem 1996; 42: 1992-1995.
23. Cavallero E, Brites F, Delfly B, et al. Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles. Arterioscler Thromb Vasc Biol 1995; 15: 2130-2135.
24. Brites FD, Cavallero E, de Geitere C, et al. Abnormal capacity to induce cholesterol efflux and a new LpA-I pre-beta particle in type 2 diabetic patients. Clin Chim Acta 1999; 279: 1-14.